Table 4.
Characteristics and results of studies assessing the adverse events and outcomes of alfuzosin versus other drugs for the treatment of benign prostatic hyperplasia.
| Study (Author) | Study type | Duration (weeks) | Treatment (daily dose) | Patients (n) | Change in symptoms (IPSS) (% or mean ± SD) | Change in Qmax (mL/s) | PVR change (mL) | Adverse Events (%) |
|---|---|---|---|---|---|---|---|---|
| Nordlinga | RCT | 12 | Alfuzosin 10 mg Alfuzosin 15 mg Tamsulosin 0.4 mg Placebo |
154 158 158 153 |
−6.5 −6.0 −6.5 −4.6 |
1.5 1.5 1.4 0.5 |
/// | 38% 39% 37% 34% |
| Buzelin et al.b | RCT | 12 | Alfuzosin 2.5 mg TID Tamsulosin 0.4 mg |
115 118 |
−3.8 −4.1 (NS) |
1.6 1.6 (NS) |
/// | 48% 53% (NS) |
| de Reijke et al.c | RCT | 14 | Alfuzosin 10 mg Doxazosin 8 mg |
105 105 |
−7.5 (±0.6) −9.2 (±0.6) (<0.05) |
2.9 (0.5) 3.0 (0.4) (NS) |
9.6 (±8.9) −29.2 (±8.6) (<0.05) |
7.5% 12% (NS) |
| Manohar et al.d | RCT | 12 | Alfuzosin 10 mg Tamsulosin 0.4 mg Silodosin 8 mg |
87 89 93 |
11.43 (±6.19) 11.03 (±5.07) 7.97 (±3.84) (NS) |
15.76 (±2.08) 14.33 (±2.15) 16.15 (±4.81) (NS) |
25.80 (±17.99) 24.42 (±14.73) 25.74 (±15.90) (NS) |
12.6% 17.9% 26.9% |
| Manjunatha et al.e | RCT | 12 | Alfuzosin 10 mg Tamsulosin 0.4 mg Silodosin 8 mg |
30 30 30 |
88.2% 72.1% 82.2% (<0.001) |
2.57 (± 4.25) 2.97 (±3.00) 1.33 (±3.00) (0.170) |
/// | /// |
| Senkul et al.f | Observational Prospective | 12 + 12 | Terazosin 5 mg versus Alfuzosin 10 mg | 40* | 18.6% (NS) 15.1% |
12.5 (%) (NS) 9.4 (%) |
/// | 1 patient in the Terazosin group |
| Lapitan et al.g | RCT | 8 | Tamsulosin 0.2 mg versus Alfuzosin 10 mg | 40 36 |
5.9 (± 5.4) (NS) 6.0 (±6.0) |
1.71 (±2.70) (NS) 0.98 (±2.87) |
/// | 25% (NS) 19.4% |
same individuals were treated with two different agents during different time frames.
Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95: 1006–1012.
Buzelin JM, Fonteyne E, Kontturi M, et al.; The European Tamsulosin Study Group (see appendix) A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 597–605.
de Reijke TM and Klarskov P. Comparative efficacy of two $α$1;-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004; 93: 757–762.
Manohar CMS, Nagabhushana M, Karthikeyan VS, et al. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial. Cent Eur J Urol 2017; 70: 148–153.
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, et al. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol 2016; 48: 134–140.
Senkul T, Yilmaz O, Iseri C, et al. Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals. Int Urol Nephrol 2008; 40: 663–666.
Lapitan MCM, Acepcion V and Mangubat J. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. J Int Med Res 2005; 33: 562–573.
IPSS: International Prostate Symptom Score; NS: non significant; PVR: post-voided residual; RCT: randomized clinical trial.